Cargando…

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Mengjie, Hu, Yujie, Lin, Gang, Chen, Chao, Li, Huafeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261849/ https://www.ncbi.nlm.nih.gov/pubmed/37325652 http://dx.doi.org/10.3389/fimmu.2023.1177085

Ejemplares similares

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
por: Liao, Xiu-Yong, et al.
Publicado: (2019)

Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma
por: Xiao, Linlin, et al.
Publicado: (2022)

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2022)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

Corrigendum: Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review
por: Xu, Tongzhen, et al.
Publicado: (2023)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions
por: Chen, Jiao-Ting, et al.
Publicado: (2023)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer
por: Wang, Yao, et al.
Publicado: (2022)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
por: Jiang, Mengjie, et al.
Publicado: (2022)

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
por: Yang, Ximing, et al.
Publicado: (2022)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma—A Real-World Multicenter Study (RICE-Retro)
por: Huang, Shujie, et al.
Publicado: (2022)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
por: Xiao, Weiwei, et al.
Publicado: (2023)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
por: Taylor, John, et al.
Publicado: (2023)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
por: Zhang, Wencheng, et al.
Publicado: (2020)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Ling, Tao, et al.
Publicado: (2022)

Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
por: Hou, Aohan, et al.
Publicado: (2020)

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
por: Xing, Wenqun, et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma
por: Qiu, Jianjian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nmq3frqfe9a8cqcselt1i2lkb2